Conviction
2 → 0
Current stock research snapshot · 8/24/26 Fresh
MEDPMedpace
Investment conviction○○○○○0 of 5 · current snapshot
Research target$445Current stock price target
Investment thesis statusINTACTLast reviewed 8/24/26
Market cap$15.36BSnapshot value · 8/24/26
Research history
See all MEDP changes ↗What changed
Target
$469.90 → $445
Last reviewed
8/19/26 → 8/24/26
Target
$470.00 → $469.90
Medpace is a full-service CRO (Phases I-IV) serving small/mid-cap biotech — the outsourced R&D engine of the healthspan/drug-development complex. Book-to-bill recovery to 1.13x with +28% new business awards signals clinical-trial demand inflecting up after the biotech funding trough; oncology/metabolic/CNS/CNS-driving mix keeps growth above sector. Research-only healthspan lane: no capital action.
Q2 2026 earnings Jul 23: rev $707.3M +17.2% YoY; diluted EPS $4.25 (+37% YoY, beat ~$3.98 est); op margin 20.8%; new business awards $795.7M +28.2% YoY; book-to-bill 1.13x (vs 0.88x prior); backlog $3.01B +4.9%; $294.7M buyback; raised FY26 guidance; stock +~15% to 52-wk high ~$678 [x.com/sec_filings_bot, x.com/StanIsTrading]. Next earnings: Q3 late Oct 2026 (TBA).
Backlog deterioration; cancellations or awards weakness; biotech funding slowdown persists
Bearish — CEO insider sells of $10M and $26M on Aug 24; listed in secondary watchlist. [X search Aug 2026]
Snapshot · 8/24/26🔴 Caution · ins-$52.9M · 13F 16+/9-×0.5 · short↓0.28
Snapshot · 8/24/26Timestamped research update
Deep research update
353 words · Updated Aug 9, 2026 · 4 sources
Research in development: this latest 353-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Medpace is a full-service clinical CRO focused on small- and mid-sized biotech sponsors, running outsourced development programs across complex therapeutic areas rather than commoditized trial management.
FY2025 revenue was $2.53B, up 20.0% YoY from FY2024; FY2025 operating income was $534.9M, implying ~21.1% operating margin. Q2 2026 revenue was $707.3M, up 17.2% YoY, and management raised FY2026 revenue guidance to $2.805B-$2.885B.
Medpace remains a leverage point on biotech sponsor funding and trial execution. The newest incremental signal is not an operating inflection but a risk check: a 2026-08-07 Form 144 covered only 795 shares, so the insider-sale bear case is immaterial versus the scale of the franchise and the backlog.
- 2026-08-07 Form 144 filed for 795 shares with aggregate market value $465,131.45 and 27,911,655 shares outstanding, which is just 0.00285% of shares outstanding.
- Q2 2026 EX-99.1 reported revenue of $707.3M (+17.2% YoY), net new awards of $795.7M, book-to-bill of 1.13x, and ending backlog of $3.014B.
- The Q2 2026 release raised FY2026 revenue guidance to $2.805B-$2.885B and implied H2 revenue of roughly $715M per quarter, near the Q2 run-rate.
- Requalification economics for a CRO switch remain the moat: supplier audit/QA, material characterization, process qualification, and comparability/regulatory filing sum to roughly 18-36 months and about $2.1M-$4.8M before any clinical bridging risk.
Sponsor qualification, data integrity, and regulatory history create switching friction that is measured in months and millions, not in vendor quotes. Once a biotech sponsor embeds a CRO like Medpace in a program, the economic cost of displacing it is large enough that the customer tends to stay unless execution fails.
- Biotech funding remains cyclical; if book-to-bill slips back below 1.0x, backlog growth can stall within a couple of quarters.
- The insider-sale stream needs continued verification, but the latest 144 is too small to matter on its own.
- Can book-to-bill sustain above 1.0x into Q3 2026, or was Q2 a temporary rebound?
- Do the late-July and early-August insider-sale filings remain routine diversification, or do they cluster into something more meaningful?
STRENGTHENED
Primary and supporting material
Sources
4 sources preserved from the latest qualified research update.